ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
10.80
+1.01 (10.32%)
Jul 17, 2025, 3:45 PM HKT
-15.36%
Market Cap3.99B
Revenue (ttm)84.64M
Net Income (ttm)-336.12M
Shares Out407.31M
EPS (ttm)-0.89
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,007,400
Average Volume4,000,850
Open10.10
Previous Close9.79
Day's Range10.00 - 11.16
52-Week Range3.21 - 22.00
Betan/a
RSI37.70
Earnings DateAug 21, 2025

About HKG:1541

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in the People’s Republic of China. The company’s core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 156
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1541
Full Company Profile

Financial Performance

In 2024, HKG:1541's revenue was 79.54 million, an increase of 933.61% compared to the previous year's 7.70 million. Losses were -315.86 million, -16.76% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.